ATNM — Actinium Pharmaceuticals, Inc.

NYSE · Health Care · Pharmaceuticals · CIK 1388320 ·
Last close
$1.16
Market Cap
$36.39M
52W High
$1.53
52W Low
$0.95
ADV30
218,590
Next earnings
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -5,903,000 -5,522,000 45,438,000 42,132,000 43,134,000
Dec 2025 0 -6,414,000 -5,940,000 51,775,000 47,998,000 43,941,000
Sep 2025 90,000 -5,692,000 -5,131,000 56,151,000 53,391,000 42,367,000
Jun 2025 0 -7,503,000 -6,878,000 63,017,000 59,928,000 44,004,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-24,580,000
Investing CF
$-104,000
Financing CF
$-217,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.26
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-409,713,000
Inventory
Receivables
ST Investments
EBIT TTM
$-36,247,000
Pretax Income TTM
$-33,887,000
Interest Exp TTM
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$90,000
EBITDA
$-25,347,000
Free Cash Flow
$-5,928,000
Enterprise Value
$-3,590,510
Total Cash
$42,132,000
Total Debt
$1,519,000
Shares Out
31,374,994
Trailing EPS
$-0.76
Book Value
$0.07
ROE
-167.7%
ROA
-28.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 90,000 -36,247,000 -33,887,000 51,775,000 43,941,000 -24,580,000
Dec 2024 0 -42,121,000 -38,243,000 76,899,000 44,141,000 -33,072,000
Dec 2023 81,000 -51,920,000 -48,818,000 81,445,000 45,066,000 -47,335,000
Dec 2022 1,030,000 -34,104,000 -33,017,000 114,192,000 47,711,000 8,644,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.48

Peers — same industry

TickerNameMarket CapLastDaily %
RADX Radiopharm Theranostics Ltd $36.34M $4.61
GRCE Grace Therapeutics, Inc. $36.52M $2.36
LITS Lite Strategy, Inc. $35.73M $1.05
VERU VERU INC. $37.08M $2.31
SDEV Stablecoin Development Corp $35.52M $1.31

News headlines (Yahoo Finance, 1h cache)

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
2026-05-06 12:00 · Yahoo
Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
2026-04-22 11:00 · Yahoo
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer
2026-04-22 11:00 · Yahoo
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
2026-04-06 11:30 · Yahoo
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
2026-02-17 12:42 · Yahoo
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?
2025-12-22 14:40 · Yahoo
Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative,
2025-12-12 13:45 · Yahoo
Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
2025-12-05 14:40 · Yahoo
Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented a
2025-12-01 13:45 · Yahoo
Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
2025-11-19 14:41 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.